



Zeal & Innovation in Medicine

Ref : ZLL/ CS/LODR/Compliance

Date : 21.04.2023

BSE Limited Department of Corporate Services, SP. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code-541400)	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol: ZIMLAB)
---	--

Dear Sir/Madam,

**Sub: Clarification on news items appearing in various Media/Publications**

With reference to certain recently published News Articles, we would like to provide the following clarifications to avoid information disparity in public at large:

We would like to inform that the company has neither received any show-cause notice nor any notice to stop manufacturing from any Drug Authority including DCGI or local drug authority as mentioned in the News Articles.

ZIM Laboratories Limited adheres to current Good Manufacturing Practices as applicable and is accredited by Regulatory Authorities for marketing and distribution of several products in India and abroad.

The Company is conscious of its disclosure obligations under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and will make disclosures if and when the same is required under the Listing Regulations.

We request you to take the above on record.

Thanking you,

Yours faithfully,  
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)  
Company Secretary and Compliance Officer  
Membership No. A38972

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur  
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,  
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960